Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model. by Thurtle, David et al.
1 
 
Individual prognosis at diagnosis in non-metastatic prostate cancer: Development and external 1 
validation of the PREDICT Prostate multivariable model 2 
David R Thurtle1,2*, David C Greenberg3, Lui S Lee4, Hong H Huang4, Paul D Pharoah5† & Vincent J 3 
Gnanapragasam1,2,6†* 4 
1. Academic Urology Group, Department of Surgery, University of Cambridge, Cambridge, UK 5 
2. Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, 6 
UK 7 
3. National Cancer Registration and Analysis Service [Eastern Region], Fulbourn, Cambridge, UK 8 
4. Department of Urology, Singapore General Hospital, Singapore 9 
5. Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, 10 
Cambridge, UK 11 
6. Cambridge Urology Translational Research and Clinical Trials, Cambridge, UK 12 
† Joint senior authors 13 
 14 




  19 
2 
 
Full title:  20 
Individual prognosis at diagnosis in non-metastatic prostate cancer: Development and external 21 
validation of the PREDICT Prostate multivariable model 22 
Short title: 23 
PREDICT Prostate: An individual prognostic model for prostate cancer 24 
Abstract 25 
Background 26 
Prognostic stratification is the cornerstone of management in non-metastatic prostate cancer (PCa). 27 
However, existing prognostic models are inadequate – often using treatment outcomes rather than 28 
survival, stratifying by broad heterogeneous groups and using heavily treated cohorts. To address 29 
this unmet need, we developed an individualised prognostic model which contextualizes PCa-specific 30 
mortality (PCSM) against other cause mortality, and estimates the impact of treatment on survival.  31 
Methods and findings  32 
Using records from the UK National Cancer Registration and Analysis Service, data were collated for 33 
10,089 men diagnosed with non-metastatic PCa between 2000 and 2010 in Eastern England.  34 
Median follow-up was 9.8 years with 3,829 deaths (1,202 PCa-specific). 19.8%, 14.1%, 34.6% and 35 
31.5% of men underwent conservative management, prostatectomy, radiotherapy and androgen 36 
deprivation monotherapy respectively. 2,546 men diagnosed in Singapore over a similar time period 37 
represented an external validation cohort.  38 
Data were randomly split 70:30 into model development and validation cohorts. 15-year PCSM and 39 
non-prostate cancer mortality (NPCM) were explored using separate multivariable Cox models 40 
within a competing risks framework. Fractional polynomials were utilised to fit continuous variables 41 
and baseline hazards. Model accuracy was assessed by discrimination and calibration using Harrell’s 42 
C-index and chi-squared goodness-of-fit respectively within both validation cohorts.  43 
 44 
A multivariable model estimating individualised 10 and 15-year survival outcomes was constructed 45 
combining age, PSA, histological grade, biopsy core involvement, stage, and primary treatment 46 
which were each independent prognostic factors for PCSM; and age and comorbidity which were 47 
prognostic for NPCM. The model demonstrated good discrimination with C-index of 0.84 (95%CI: 48 
0.82-0.86) and 0.84 (95%CI: 0.80-0.87) for 15-year PCSM in the UK and Singapore validation cohorts 49 
respectively, comparing favourably to international risk-stratification criteria. Discrimination was 50 
maintained for overall mortality with C-index 0.77 (95%CI: 0.75-0.78) and 0.76 (95%CI: 0.73-0.78). 51 
The model was well-calibrated with no significant difference between predicted and observed PCa-52 
specific (p=0.19) or overall deaths (p=0.43) in the UK cohort.  53 
Key study limitations were a relatively small external validation cohort, an inability to account for 54 
delayed changes to treatment beyond 12 months and an absence of t-stage sub-classifications.  55 
Conclusions 56 
‘PREDICT Prostate’ is an individualised multivariable PCa prognostic model built from baseline 57 
diagnostic information and the first to our knowledge which models potential treatment benefits on 58 
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overall survival. Prognostic power is high despite using only routinely collected clinico-pathological 59 
information.    60 
Author Summary 61 
Why was this study done? 62 
- Among men with non-metastatic prostate cancer a number of treatment options are often 63 
appropriate, including surveillance or conservative management.  64 
- Problems of both over-treatment of indolent disease and under-treatment of aggressive 65 
disease are both recognised. Many men also suffer lifelong side-effects from a treatment 66 
they may not have not needed. 67 
- Estimating prognosis is therefore of crucial importance to inform decision-making on the 68 
benefits of treatments at the point of diagnosis. However, existing risk models are 69 
inadequate, rarely use survival as an outcome, ignore non-cancer mortality, and often group 70 
patients into broad categories. As a result no model is yet to be formally endorsed or widely 71 
used in clinical practice.  72 
- In this study we sought to create an individualised model that addresses these gaps and 73 
predicts both cancer-specific and overall survival at the point of diagnosis, and which 74 
estimates the potential survival benefit of treatment.  75 
What did the researchers do and find? 76 
- We studied a large UK dataset of over 10,000 men diagnosed with non-metastatic prostate 77 
cancer and long-term survival information. The dataset was randomly split into model 78 
development and validation datasets. An additional dataset of over 2500 men diagnosed in 79 
Singapore was used for additional external validation. 80 
- Using Cox regression and fractional polynomials, models were built for 15-year prostate 81 
cancer specific mortality and non-prostate cancer mortality using patient and tumour 82 
characteristics routinely available at diagnosis. These two models were then adjusted for 83 
competing risks to predict overall mortality.  84 
- We found that the new risk model, called ‘PREDICT Prostate’ predicted survival outcomes 85 
with a high degree of accuracy in both validation sets with concordance indices up to 0.84. 86 
- We have now incorporated the model into a web-based interface for easy access and utility. 87 
What do these findings mean?  88 
- To our knowledge, we present the first individualised multivariable survival model for non-89 
metastatic prostate cancer built and validated in an unscreened, pre-treatment cohort. 90 
- Our findings need further validation in independent datasets, and may be limited by a 91 
relatively small external validation cohort.  92 
- This tool incorporates the impact of radical therapy, which allows comparison to be made 93 
against the option of conservative management within the context of an individual’s 94 
competing risks, to inform decision-making around management.  95 
- The model does not require any additional tests beyond standard of care, and is freely 96 
available for use. It’s primary application is among men deciding between conservative 97 
management and radical treatment – where decision dilemmas are most acute.  98 
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- The model has the potential to enable well-informed and standardised decision-making and 99 
reduce both over- and under-treatment.  100 
 101 




Prostate cancer (PCa) is the commonest cancer affecting males and a leading cause of cancer-related 104 
morbidity[1].  The vast majority of these new presentations are with localised or locally advanced 105 
disease, representing a significant healthcare and economic burden [2]. Treatment decisions are 106 
notoriously complex with the risk of cancer related mortality balanced against the potential 107 
morbidity associated with treatment as well as competing mortality risks. Estimating prognosis 108 
within these contexts is therefore highly important, with over 40,000 consultations for newly 109 
diagnosed PCa every year in the UK alone[2]. This importance has been underlined by randomised 110 
trial evidence reporting non-inferiority of conservative management compared to radical therapy in 111 
many early cancers from the American PIVOT and UK ProtecT trials[3,4]. 112 
Despite this importance, there are no high quality individualised prognostic models available for 113 
clinical counselling and decision-making. Instead, tiered stratification systems are used that 114 
categorise men into different levels of risk. These models are widely endorsed by national and 115 
international guideline groups but are often derived using inadequate surrogate endpoints, such as 116 
PSA resurgence after treatment, rather than being calibrated against mortality[5,6]. Modern 117 
extensions to these models have now sought to validate performance against cancer mortality and 118 
have extended the number of sub-classifications[7-10].  Although these extensions add granularity 119 
they remain too heterogeneous for modern individualised medicine approaches. More recent 120 
attempts at developing survival models have focussed solely on men undergoing radical treatment, 121 
and have not been appropriately validated[11,12]. The inadequacies of existing models are evident 122 
by the fact that the American Joint Committee on Cancer (AJCC) have not endorsed a single 123 
prognostic model for non-metastatic PCa[13].  124 
The objectives of this study were to develop and validate an individualised prognostic model for 125 
non-metastatic PCa. Our aim was to produce a model that was able to contextualise the relative 126 
PCa-specific and overall survival outcomes for an individual with newly diagnosed disease and allow 127 
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modelling of the potential benefit of treatment on these outcomes. Study design and reporting was 128 




This study is reported throughout as per the Transparent Reporting of a multivariable Prediction 131 
model for individual prognosis or Diagnosis (TRIPOD) guideline (S1 Checklist). 132 
Study population and definition of variables 133 
Fully-anonymised data were retrieved from Public Health England after review by the Office for Data 134 
Release(ODR1617/171).  Following approvals, Cambridge University Hospitals NHS Trust acted as 135 
host institution for data receipt. Information on all men diagnosed with non-metastatic PCa in 136 
secondary care in Eastern England, UK, between 2000 and 2010 was collected prospectively by the 137 
National Cancer Registration and Analysis Service [NCRAS] Eastern Region. The cohort derivation has 138 
been previously described[16]. Men with recorded nodal or metastatic disease at diagnosis were 139 
excluded, along with men diagnosed only by endoscopic resection and any remaining men with PSA 140 
≥100ng/ml as a surrogate for occult metastatic disease[17]. Only men with intact information on key 141 
candidate predictors – age, PSA (ng/ml), histological grade group, T-stage and primary treatment 142 
were included. From a potential cohort of 15,335 men, 5,246 (34.2%) were excluded for missing 143 
information in at least one of these variables leaving a final analytic cohort of 10,089.   Comorbidity 144 
scores, derived from inpatient hospital episode statistics (HES) data were also included. These are 145 
based on clinical coding of inpatient episodes in the period between 27 and 3 months before PCa 146 
diagnosis, thus excluding PCa from any comorbidity score.  Vital status was ascertained at the end of 147 
March 2017 with all analyses censored at the end of September 2016 to allow for a lag-time of up to 148 
6 months for non-cancer deaths through the National Health Service Strategic Tracing Service. Death 149 
was considered PCa-specific when PCa was listed in 1a, 1b or 1c of the death certificate. 150 
Potential variables entered into the primary model were age, PSA, clinical T-stage, histological grade, 151 
ethnicity, comorbidity and primary treatment type. Information from NCRAS was that recorded at 152 
the time of diagnosis. T-stage was simplified to T1, T2, T3 or T4 as subcategories were rarely 153 
available and have limited impact in determining prognosis[18]. Histological grade groups (1-5) were 154 
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used([19]. PSA (ng/ml) refers to the value at diagnosis, prior to biopsy or treatment. Primary 155 
treatment refers to the first definitive treatment the patient received in the first 12 months. Here we 156 
have used the term conservative management to cover active surveillance and watchful waiting as 157 
registry data did not discriminate between the two during this time period. As previously published, 158 
the majority of men receiving radiotherapy (RT) in this period were on concomitant hormone 159 
therapy which represents current best practice for this treatment modality[20]. 160 
Model Development 161 
The primary (UK) cohort was split randomly in a 70:30 ratio into model development (n=7062) and 162 
validation cohorts (n=3027) (Table 1). Within the development cohort separate models were built 163 
for PCa-specific mortality (PCSM) and non-PCa mortality (NPCM). The general approach to modelling 164 
was similar to that used for the PREDICT breast cancer prognosis and treatment benefit model[21]. 165 
Cox proportional hazards models were utilised to estimate hazard ratios associated with each 166 
candidate predictor. Follow up time was censored at time to death, time to last follow up or 15 167 
years, which ever came first. Each variable was assessed through uni- and multi-variable analysis 168 
with the proportional hazards assumption tested. A backwards elimination technique was used for 169 
variable selection with a 5% significance level. Risk-relationships between continuous variables were 170 
modelled using multivariable fractional polynomials, with continuous data retained wherever 171 
possible to maximise predictive information. T-stage, histological grade group, and primary 172 
treatment type were modelled as factor variables. Radical treatments (radiotherapy (RT) or radical 173 
prostatectomy (RP)) were combined, as explained later.  After fitting the multi-variable models, 174 
smoothed functions for the baseline hazard of PCSM and NPCM were calculated.  The baseline 175 
cumulative hazard was estimated for each patient, then the logarithmic value of the baseline hazard 176 
was regressed against time using a univariate fractional polynomial function[21].  177 
Competing risks adjustment  178 
Beta coefficients for each prognostic factor in the two Cox models were used to derive a prognostic 179 
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index for PCSM (piPCSM) and NPCM (piNPCM) for each patient. The absolute risk (hazard(H)) of PCa 180 
death (HPCa) and non-PCa (HNPC) death until time t, if there were no competing mortalities, are 181 
estimated by the following formulae respectively: HPCa = 1 – exp(-exp(piPCSM)*bhPCSM(t))  and HNPC 182 
= 1 – exp(-exp(piNPCM)*bhNPCM(t)). Where bhPCSM(t) and bhNPCM(t) are the cumulative baseline 183 
hazards of PCSM or NPCM at time t respectively.  However, as these risks compete against each 184 
other, the cumulative risk (R) of overall mortality (OM) at time t is : ROM(t) = 1 – (1-HPCA(t))*(1-HNPC(t). 185 
Therefore the formulae for cumulative risk (R) of PCa death and non-PCa death at time t are: RPCa(t) =  186 
ROM(t) * (HPCa(t) /(HPCa(t)+HNPC(t)) and RNPC(t) = ROM(t) * (HNPC(t) /(HNPC(t)+HPCa(t)) respectively.  The 187 
source code for replicating the model’s output has been made available online, including this 188 
competing risk adjustment.  189 
Model accuracy and comparison to existing models 190 
Model calibration and goodness-of-fit was investigated in the UK validation cohort by comparing 191 
observed and predicted deaths within quintiles of predicted mortality and within strata of other 192 
prognostic variables. For assessing calibration, we integrated the predicted outcomes across all 193 
follow-up times to allow for cases with follow-up of less than 10 or 15 years. Thus the calibration 194 
corresponds to a range of different follow-up times.  A simplified χ2 goodness-of-fit (GOF) test was 195 
performed using the method of May and Hosmer, whereby a p value of less than 0.05 would suggest 196 
a significant difference between the expected and observed number of events, assessed up to 10 197 
years or 15 years[22]. Calibration curves were also visually assessed. Model discrimination was 198 
evaluated by estimating 10 and 15-year cumulative mortality risk. Harrell’s concordance statistic (C-199 
index) was then calculated for PCa-specific, non-PCa and overall deaths. This accounts for right-200 
censored data, i.e. cases with less than 10 or 15 years follow-up respectively.  All analyses were 201 
performed using Stata 14 (StataCorp, College Station, TX, USA), with the exception of C-index which 202 
was performed using ‘rcorr.cens’ within the ‘Hmisc’ package of R[23]. 203 
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Comparisons against existing models were made by calculating C-indices for 3 well-known tools used 204 
at the point of diagnosis internationally – namely the UCSF Cancer of the Prostate Risk Assessment 205 
(CAPRA) score, the updated NCCN criteria and the three-tier EAU criteria [7,10,24]. Available 206 
information was used to calculate these with no imputation of missing data. Where T stage sub-207 
classification was unknown, integer T stages were used.  208 
External validation 209 
External validation of the model was assessed using a geographically and ethnically independent 210 
cohort of men from Singapore General Hospital, diagnosed between 1990 and 2015 which has been 211 
previously described[25]. The same inclusion criteria were applied as to the model development 212 
dataset. From a potential cohort of 3245, 699 (21.5%) were excluded for missing information. 310 213 
cases had missing data for key candidate predictors, and no follow-up was available for a further 389 214 
men, leaving a final analysable cohort of 2,546 (Table 1).  Data amongst this cohort had been 215 
recorded on a prospective basis including the same parameters, defined identically as the primary 216 
cohort with the addition of biopsy information, but did not include comorbidity information. NPCM 217 
estimates therefore assumed the same prevalence of comorbidity as the primary dataset (10.21%) 218 
spread evenly across the cohort. Vital status was ascertained via the Singapore Ministry of Home 219 
Affairs, using the same definitions for cause of death, with data censored 30th June 2017.  Model 220 
performance was assessed using the methods described above. Ethics for use of these data is 221 
covered by ref. 2009/1053/D approved by the SingHealth Centralised Institutional Review Board. 222 
Inclusion of biopsy information as a variable 223 
Previous risk criteria have included diagnostic biopsy information as a potentially important 224 
prognostic variable. To investigate this we undertook an additional sub-cohort analysis on men 225 
diagnosed at one hospital within our cohort (n=1451) for whom biopsy characteristics were 226 
available. For this we used percentage of positive cores (PPC = number of cores positive for 227 
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cancer/total number of cores taken). PPC was regressed against PCSM, offset against all parameters 228 
within the base model. PPC was modelled continuously and categorically. Likelihood ratio χ2tests, 229 
Akaike(AIC) and Bayesian information criterion(BIC) were used to determine best fit. The eventual 230 
parameter was weight-adjusted and incorporated in to the model (Tables F and G in S1 Appendix). 231 
Performance of the extended model, including the PPC parameter, was then assessed within the 232 





The model development cohort consisted of 7,063 men; 842 and 1,821 men died from PCa and 236 
other causes within 15 years respectively.  The UK validation cohort consisted of 3,026 men; 360 and 237 
806 died from PCa and other causes respectively.  Median follow-up was 9.8 years for both cohorts 238 
with 82,887 person-years of follow-up in total (Table 1). Importantly, the UK cohort included 239 
significant numbers of patients who had undergone conservative management (n=1997). Only 114 240 
(5.7%) of these men converted to radical treatment over total study follow-up.  Trends across the 241 
inclusion period, including increased proportions of T1 disease and increasing uptake of conservative 242 
management have been identified previously(16, 20).  243 
  244 
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Total Subjects 10,089  7,063  3026  2546   
Time at risk (years) 82,887  58,138  24,750  13,416   







10 year outcomes:  %  %  %  % 
PCa deaths 1030 10.2 712 10.1 317 10.5 105 4.1  
Non PCa deaths 2246 22.3 1555 22.0 691 22.8 225 8.8  
Any-cause death 3276 32.5 2267 32.1 1008 33.3 330 13.0  
Observations censored before 10 years 3770 37.4 2667 37.8 1103 36.5 1930 75.8 
15-year outcomes:          
PCa deaths 1202 11.9 842 11.9 360 11.9 133 5.2  
Non PCa deaths 2627 26.0 1821 25.8 806 26.6 283 11.1  
Any-cause death 3829 38.0 2663 37.7 1166 38.5 416 16.3  
Observations censored before 15 years 6000 59.5 4212 41.7 1788 59.1 2063 81.0 
Crude PCS mortality rate (per patient year) 1.46  1.46  1.46  0.99   
Annual overall mortality rate (per patient 
year) 4.64 
 4.6  4.72  3.1   
Age (mean, SD) 69.9 8.30 69.9 8.34 69.9 8.29 66.1 7.96 
PSA (mean, SD) 18.4 17.5 18.5 17.5 18.2 17.6 15.7 16.6 
Gradegroups  %  %  %  % 
1 3328 33.0 2317 32.8 1011 33.4 1126 44.2 
2 3017 29.9 2125 30.1 892 29.5 723 28.4 
3 1486 14.7 1057 15.0 429 14.2 326 12.8 
4 1032 10.2 710 10.1 322 10.6 170 6.7 
5 1226 12.2 854 12.1 372 12.3 201 7.9 
Tumour-stage          
1 5421 53.7 3761 53.2 1660 54.9 1625 63.8 
2 3213 31.8 2270 32.1 943 31.2 660 25.9 
3 1378 13.7 977 13.8 401 13.3 244 9.6 
4 77 0.8 55 0.8 22 0.7 17 0.7 
Primary Treatment          
Radical Prostatectomy 1419 14.1 995 14.1 424 14.0 1012 39.7 
Radiotherapy 3495 34.6 2457 34.8 1038 34.3 823 32.3 
Hormone Monotherapy 3178 31.5 2226 31.5 952 31.5 164 6.4 
Conservative Management 1997 19.8 1385 19.6 612 20.2 538 21.1 
Missing na  na  na  9 0.4 
Ethnicity          
White 7804 77.4 5464 77.4 2340 77.3 36 1.4 
Missing/unknown 2136 21.2 1491 21.1 641 21.3 0 0.0 
Asian 50 0.5 35 0.5 15 0.5 2435 95.6 
Other 99 1.0 108 1.5 26 0.9 73 2.9 
Table 1 Baseline cohort characteristics in the UK cohort overall, model development and validation cohorts 245 
and the external Singapore cohort.  246 
PCa = prostate cancer SD= standard deviation  247 
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Model development and specification 248 
Age, PSA, histological grade group, clinical stage and primary treatment type were all independent 249 
predictors for PCSM in the development cohort (Table 2). Comorbidity had a predictive effect in 250 
relation to NPCM but not PCSM. Age was also independently prognostic for NPCM. In the final 251 
model, comorbidity was modelled as a binary variable (0 or ≥1). The hazard ratios and fractional 252 
polynomial (FP) functions for prognostic factors in the final model are shown in Table 2. Associated 253 
FP functions for age and PSA are plotted in Fig 1. These allow more flexibility in relationships for 254 
continuous variables. The estimated baseline survival functions for PCSM and NPCM are recorded in 255 
S1 Appendix, and plotted against actual baseline PCSM and NPCM in Fig E in S1 Appendix. 256 
 257 
  Prostate Cancer Specific Mortality 
  HR 95%CI P 
Age FP 1.003 1.002-1.003 <0.001 (age/10)^3 -341.16 
PSA FP 1.204 1.092-1.328 <0.001 ln((psa+1)/100)+1.6364 
Grade group       
1 1.00 - - 
2 1.32 1.06-1.65 0.014 
3 1.73 1.36-2.19 <0.001 
4 2.10 1.63-2.69 <0.001 
5 3.93 3.15-4.89 <0.001 
T stage       
1 1.00 - - 
2 1.18 1.01-1.37 0.042 
3 1.49 1.23-1.80 0.000 
4 1.88 1.14-3.13 0.014 
Primary Treatment        
Conservative management 1.00 - - 
Radical treatment (RP/RT) 0.50 0.38-0.67 <0.001 
Hormone monotherapy 2.48 1.92-3.20 <0.001 
        Non Prostate Cancer Mortality 
Age FP 1.13 1.12-1.14 <0.001 age-69.87 
Comorbidity Score       
1+ 1.89 1.67-2.14 <0.001 
Table 2 The hazard ratios and p values of the variables included in each of the prostate cancer specific 258 
mortality and non-prostate cancer mortality models.  259 
FP = fractional polynomial HR = hazard ratio CI = confidence interval  260 
 261 




 Figure 1 Prostate cancer-specific mortality (PCSM) hazard ratio functions for age (left) and PSA 264 
(centre), and non-PCa mortality (NPCM) hazard ratio function for age (right). Each derived from the 265 
model development data.  266 
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UK validation 267 
The model was well-calibrated within the East of England validation cohort with absolute differences 268 
between observed and predicted PCa-specific and overall deaths less than 1% at 10 years (Table 3). 269 
The GOF tests suggested the model fitted well across different quintiles of risk, as shown by the 270 
calibration curves (Fig 2) with no significant difference in observed and predicted PCa-specific 271 
(p=0.19) or overall deaths (p=0.43) over 10 years (Table 3).  Model discrimination was good, 272 
particularly for PCa-specific mortality, with C-index 0.84 (95%CI 0.82-0.86) and 0.84 (95%CI: 0.82-273 
0.86) over 10 and 15 years follow up respectively (Table 3). Within the UK cohort, model 274 
discrimination was superior (p<0.001) to the current EAU, NCCN and CAPRA risk-stratification criteria 275 
for both PCSM and overall mortality (Table 4).  276 
 277 
  Predicted Observed Difference (%)  
χ2 GOF  
C-index 95%CI 
p value 
10 years follow-up       
PCa Deaths 343 317 -0.86 0.19 0.84 0.82-0.86 
Non-PCa 
deaths 641 691 1.65 0.19 0.74 0.72-0.77 
Overall deaths 986 1008 0.73 0.43 0.77 0.75-0.78 
15 years follow-up       
PCa Deaths 413 360 -1.75 0.04 0.84 0.82-0.86 
Non-PCa 
deaths 751 806 1.82 0.02 0.71 0.69-0.72 
Overall deaths 1165 1166 0.03 0.63 0.77 0.75-0.78 
Table 3 Observed and predicted deaths over 10 and 15 years in the UK validation cohort (n=3026). Goodness 278 
of fit (GOF) and C-index are shown for each cause of death. 279 
 280 




Figure 2 Calibration curves comparing observed and predicted probability of prostate cancer(PCa) (left), non-283 
PCa (centre) and overall (right) deaths at 10 years by quintile of risk within the UK validation cohort.  284 




  PCSM     Overall Mortality   
Model C-index 95% CI p C-index 95% CI p 
PREDICT 0.843 0.824-0.862 - 0.766 0.753-0.780 - 
EAU 0.688 0.665-0.711 <0.001 0.628 0.613-0.643 <0.001 
NCCN 0.720 0.695-0.744 <0.001 0.644 0.628-0.659 <0.001 
CAPRA 0.754 0.728-0.779 <0.001 0.656 0.640-0.672 <0.001 
Table 4 Discrimination of the model, compared to other existing models amongst the UK validation cohort 287 
over 15 years maximum follow-up (n=3026).  288 
EAU = European Association of Urology NCCN = National Comprehensive Cancer Network  CAPRA = Cancer of 289 
the Prostate Risk Assessment (UCSF) 290 
 291 
Calibration remained good across various sub-categories of patients, as demonstrated in Table C in 292 
S1 Appendix. Importantly, predictions for both PCa and non-PCa deaths amongst men undergoing 293 
either conservative management or radical therapy were within 2%. The GOF tests amongst this 294 
treatment sub-cohort continued to demonstrate no significant difference between predicted and 295 
observed PCa-specific (p=0.23) or overall deaths (p=0.11) over 10 years.  296 
 297 
External Validation 298 
Accuracy of the model, was also assessed using the Singaporean cohort (n=2,546). Here, median 299 
follow-up was 5.1 years, with 133 and 283 PCa and non-PCa deaths respectively (Table 1).  300 
Model discrimination amongst this cohort was promising with C-index 0.83 (95%CI: 0.79-0.87) and 301 
0.76 (95%CI 0.73-0.78) for PCSM and overall mortality respectively over 10 years (Table 5). 302 
Differences between observed and predicted deaths were less than 1% over 10 and 15-years, albeit 303 
within a small cohort (Table 5). GOF analysis showed no significant differences between observed 304 
and predicted non-PCa deaths, but the model appeared to slightly underestimate PCSM and overall 305 
deaths (Table 5 and Fig F in S1 Appendix).  Within this external cohort, our baseline model 306 
performed better than the 3 tested comparators in predicting overall mortality (P<0.001) (Table D in 307 
S1 Appendix). Discrimination for PCSM was improved compared to the EAU stratification criteria, but 308 
not significantly better than the NCCN or CAPRA scores.  309 
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10 years follow-up       
PCa Deaths 89 105 0.63 0.01 0.83 0.79-0.87 
Non-PCa 
deaths 236 225 -0.43 0.10 0.74 0.70-0.77 
Overall deaths 325 330 0.20 0.01 0.76 0.73-0.78 
15 years follow-up       
PCa Deaths 112 127 0.59 0.00 0.82 0.78-0.86 
Non-PCa 
deaths 279 273 -0.24 0.08 0.72 0.69-0.76 
Overall deaths 391 400 0.35 0.01 0.75 0.72-0.78 
Table 5 Observed and predicted deaths over 10 and 15 years in the Singaporean validation cohort (n=2546). 310 




Model extension and re-testing with the inclusion of diagnostic biopsy information   313 
After assessing multiple categorisations of PPC, PPC was integrated into the model using a 314 
dichotomous variable around a cut-off of 50% (Tables E and F in S1 Appendix). PPC <50% or ≥50% 315 
were associated with adjusted hazard ratios for PCSM of 0.54 and 1.78 respectively. A hazard ratio of 316 
1.0 is applied if PPC is unknown or to omit the PPC variable (Table G in S1 Appendix).  317 
Accuracy of the final extended model, incorporating PPC, was re-assessed using the Singaporean 318 
cohort (n=2,546). Model discrimination was slightly improved compared to the baseline model with 319 
C-index 0.85 (95%CI: 0.82-0.88) and 0.76 (95%CI 0.73-0.79) for PCSM and overall mortality 320 
respectively (Table H in S1 Appendix).  Calibration was also improved with the incorporation of the 321 
PPC variable (Fig K in S1 Appendix). GOF analysis showed no significant difference between observed 322 
and predicted PCa-related deaths (p=0.11) although the model still appeared to slightly 323 
underestimate PCSM. Calibration within subgroups (Table J in S1 Appendix) suggested the model 324 
underestimated PCSM in the context of very high-risk characteristics: grade group 5 (predicted: 30.6, 325 
observed: 36), t-stage 4 (predicted: 4.1, observed: 8) and PSA >50ng/ml (predicted: 21, observed: 326 
25).  327 
Next, we compared accuracy of our extended model to existing PCa models within this external 328 
cohort. The model continued to out-perform existing models in predicting overall mortality 329 
(p<0.001) (Table 6). For PCSM, improved C-indices were observed for PCSM compared to existing 330 
models, but again only reached significance compared to the EAU criteria. Finally, we limited the 331 
cohort to only men who received conservative management or radical treatment, to model 332 
contemporary practice where primary hormone therapy is less commonly used(20). Again, the 333 
model generally showed superior discrimination compared to other models (Table K in S1 Appendix).  334 
 335 
 336 




  PCSM     Overall     
Model C-index 95% CI p C-index 95% CI p 
PREDICT 0.838 0.804-0.872 - 0.756 0.728-0.784 - 
EAU 0.763 0.732-0.794 0.001 0.637 0.606-0.667 <0.001 
NCCN 0.804 0.767-0.841 0.182 0.649 0.616-0.682 <0.001 
CAPRA 0.822 0.785-0.860 0.530 0.671 0.638-0.704 <0.001 
 339 
Table 6 Discrimination of the extended model, compared to other existing models amongst the Singaporean 340 
cohort over 15 years maximum follow-up (n=2546).  341 
EAU = European Association of Urology NCCN = National Comprehensive Cancer Network CAPRA = Cancer of 342 
the Prostate Risk Assessment (UCSF) 343 
 344 
Proposed clinical utility of the model 345 
To establish utility of the tool for clinicians and patients we have developed a web based interface 346 
for free access to the model. We expect that primary utility will be among men for whom 347 
conservative management and radical treatment might both be appropriate options.  Example 348 
outputs from this web tool for 3 hypothetical vignettes are demonstrated in Fig 3.  The age and 349 
comorbidity status at diagnosis are altered within each case to demonstrate the impact of 350 
competing risks on treatment benefit. With increasing age and comorbidity, reductions in PCSM 351 
achieved by radical treatment are attenuated by increased rates of NPCM as the risks of PCSM and 352 
NPCM compete against one another. For example a 72 year-old with comorbidity and the disease 353 
characteristics shown in Case B has an estimated 19.6% 15-year risk of prostate cancer death when 354 
conservatively managed. Although the estimated PCSM is reduced to 11.1% by treatment, the 355 
overall survival improves by only 3.8%, whereas for a younger man the majority of PCSM benefit 356 
translates into overall survival benefit (Fig 3).  357 




Figure 3 Example model outputs using 15-year overall survival curves for three hypothetical vignettes A, B and 360 
C. Only age and comorbidity status has been changed between each column to demonstrate the reduction in 361 
benefit from radical treatment when competing risk increases.  362 
PSA = Prostate specific antigen cT = clinical tumour stage GG = histological grade group ‡ Comorbidity refers to 363 
a patient with Charlson score of 1 or more who has been admitted to hospital in the 2 years prior to prostate 364 




In this study, to our knowledge, we present the first individualised multivariable prognostic model 367 
for non-metastatic PCa built and validated in an unscreened, pre-treatment cohort. We show that 368 
this model, hereafter referred to as PREDICT Prostate, is able to derive predictions for PCa and 369 
overall mortality with a high degree of concordance by using routinely available diagnostic clinico-370 
pathological data, and appears to outperform existing models. The model incorporates the impact of 371 
radical therapy, which allows comparison to be made against the option of conservative 372 
management within the context of an individual’s competing risks. Importantly, the model does not 373 
require any additional tests or information, but could be refined in the future if additional 374 
independent factors with proven prognostic value are established.  375 
PCa incidence is rising with an ageing male population and increased testing. In the UK alone, the 376 
incidence is projected to rise by 69% by 2030[26]. Over 84% of UK men have non-metastatic disease 377 
at presentation with more than half of these classified as low or intermediate-risk using traditional 378 
risk criteria[2]. Level 1 evidence shows that many men with these disease characteristics will not 379 
benefit from immediate radical therapy, with the randomised ProtecT and PIVOT trials reporting no 380 
survival differences in men managed by intervention or conservative management after 10 years of 381 
follow up[3,4]. Additionally, radical treatment is associated with risks of significant adverse effects 382 
including incontinence, impotence, bowel dysfunction and long-term decisional regret[27,28]. 383 
Unsurprisingly, conservative management or active surveillance is therefore becoming increasingly 384 
popular in low-risk disease, and emerging evidence also suggests very favourable outcomes in 385 
intermediate-risk disease[29].  386 
Identifying men appropriate for initial conservative management and conveying this information to 387 
an individual within their own context of competing mortality is currently an imprecise exercise, with 388 
a lack of objective data on potential outcomes. Instead, most current prognostication is directed by 389 
categorisation of men into risk stratified criteria and discussions with clinicians who may or may not 390 
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be PCa-specialists and are potentially conflicted by a bias to a treatment they offer [8-10,30].  391 
PREDICT Prostate was conceived to address this critical gap in clinical need and better inform and 392 
standardise the decision-making process. It is built around long-term actual survival data and has 393 
been designed to address all AJCC criteria[14]. The model incorporates variables available for almost 394 
any man diagnosed around the world and has wide potential applications in informing patient, 395 
clinician and multi-disciplinary team decision-making to reduce both over and under-treatment[31]. 396 
Abundant literature shows that better decision aids contribute to more knowledgeable, informed 397 
patients and that this improves clinician-patient communication[32,33]. Therefore, we anticipate our 398 
model will be widely acceptable and highly impactful, although formal clinical impact assessments 399 
will also be undertaken[34].  400 
The parameters used within PREDICT Prostate for PCSM are well established independent variables 401 
such as Grade group, PSA and T Stage[35-37]. Here, they have been combined in a novel way and by 402 
utilising fractional polynomials to maintain as much predictive information as possible.  PREDICT 403 
Prostate is also distinctive in estimating the competing risks of PCSM and NPCM to accurately model 404 
overall mortality. The model deliberately uses histological grade groups (1-5) as we standardise 405 
practice towards this more-intuitive scale[19].  Biopsy information was integrated as an optional 406 
variable in PREDICT Prostate as biopsy quantification is accepted as a surrogate for tumour volume. 407 
However, no consensus on the best methodology for its assessment yet exists, with few studies 408 
exploring its relationship with long-term survival[38]. Hence we used a pragmatic assessment of this 409 
by using the simplest common denominator, the number of positive versus overall biopsy cores 410 
taken (PPC).  Our data showed an independent prognostic impact around the dichotomous cut-off of 411 
<50% versus ≥50% PPC. This is the same cut-off reported in two American studies exploring survival, 412 
where effect size is comparable. This cut-off has now also been integrated into the latest NCCN risk-413 
criteria[10,39,40].  PPC thus maintains simplicity and facilitates ease of interpretation (although the 414 
model can function without biopsy information). During the study period local practice was to 415 
perform 12-core systematic trans-rectal biopsy. However, contemporary practice in prostate biopsy 416 
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is evolving with the use of more image-targeting[41].  It is unknown how these changes will alter the 417 
prognostic value of biopsy involvement. In the meantime, we recommend adherence to the AUA 418 
guidelines which suggest any biopsies from a target are considered as a single core if taken as part of 419 
a ‘target and systematic’ biopsy approach[9].  420 
A key question whilst developing PREDICT Prostate was whether to use data-derived coefficients for 421 
treatment effect or published trial data. Ultimately the data-derived coefficient for the combination 422 
of radical treatment types was used, with a hazard ratio of 0.50 (95%CI 0.38-0.67). This is in fact very 423 
similar to published randomised controlled trial data of treatment effect e.g. PIVOT (RP vs AS: HR 424 
0.63 95%CI: 0.36-1.09) and ProtecT trials (RT vs active monitoring: HR 0.51 95%CI: 0.15-1.69. RP vs 425 
active monitoring: 0.63 95%CI: 0.21-1.93)[3,4]. In the web-based presentation of the model, 426 
uncertainty around treatment effect is demonstrated by displaying treatment benefit from 0-100% 427 
of PCSM around the estimated survival (Fig 3). Separate presentation of RT and RP outcomes was 428 
not explored as no adequate randomised data yet shows a survival difference between the two 429 
treatment approaches[4,42]. One caveat in the clinical utility of PREDICT Prostate is that primary 430 
androgen deprivation, used in a proportion of our study cohorts, is now seldom used as a first line 431 
therapy. Indeed, within this cohort the poor prognosis apparently associated with primary androgen 432 
deprivation is likely to reflect a selection bias towards men unfit for other treatment options, or with 433 
potentially occult metastatic disease. Our model however is primarily for use among men deciding 434 
between conservative management and radical treatment – where decision dilemmas are most 435 
acute. Indeed, as shown in Table C in S1 Appendix, calibration of the model was best amongst men 436 
with low to intermediate-risk features where this model would be most useful and appropriate in 437 
clinical decision-making. Using disease status information from the National Prostate Cancer Audit, 438 
this may represent up to 47% of all newly diagnosed prostate cancers[2]. 439 
Particular strengths of PREDICT Prostate include the derivation from a large cohort from a 440 
geographical area straddling 2 academic centres and 9 general hospitals. These data were collected 441 
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prospectively by an independent cancer registry with accurate death certificate notification, avoiding 442 
many potential biases associated with single-centre studies. The accuracy of UK PCa cause of death 443 
reporting is also known to be very reliable[43]. However, we do acknowledge limitations in the 444 
model. We do not have data on MRI-defined lesions or radiological stage. However, it is yet 445 
unknown if these data will improve prognostic ability with MRI primarily used to guide biopsies 446 
rather than offer prognostic information.  Indeed, the additional value of MRI in detecting missed 447 
cancers is debatable given that men with a missed cancer using non-imaging approaches have 448 
extremely low rates of PCa death[44]. The model also does not currently integrate genomic tests or 449 
molecular markers. However, the most established tools such as Prolaris CCP and Oncotype DX GPS 450 
have predominantly been tested against shorter-term outcomes in very selected groups, particularly 451 
in the post-treatment setting[45,46]. When these expensive tools have been assessed against PCSM, 452 
concordance is very similar to our model. For example the Decipher genomic classifier alongside 453 
CAPRA showed an AUC of 0.78 (95%CI 0.68-0.87) for 10-year PCSM following prostatectomy[47]. We 454 
agree with others, that good data should be sought as to whether any such marker truly adds 455 
independent prognostic information beyond a gold-standard multivariable model[48].  As with MRI, 456 
if one or more marker does show independent prognostic value in the future it can be included in 457 
future refinements to PREDICT Prostate[49]. By using real world data, our treatment categories were 458 
based upon actual treatments received as opposed to assigned treatments as is often problematic in 459 
randomised trials[4]. However, our analysis cannot account for the impact of delayed conversions to 460 
treatment beyond 1 year, albeit the number of men switching from conservative management was 461 
very small (5.7%). A final potential limitation of the model is the lack of t-stage sub-classifications. 462 
However, it is accepted that t stage is often inaccurately assigned in localised disease[18].   463 
In terms of statistical approach, we recognise that more complex flexible parametric survival 464 
modelling frameworks exist. For example, there are several penalized regression approaches such as 465 
LASSO, ridge-regression and random forests which could have been applied. However, we have used 466 
an established methodology, which in other tumour types could not be improved upon by more 467 
27 
 
complex approaches[50]. Our approach also has the advantages of allowing straight-forward 468 
external validation and the incorporation of additional parameters should sufficient evidence 469 
support their inclusion, as demonstrated by updates to the PREDICT breast cancer model[51].  We 470 
also appreciate that our external validation cohort was relatively small, and different from our model 471 
development dataset. Gaining access to well-annotated cohorts with long term follow-up outcomes 472 
is difficult, this dataset represented the best independent cohort available to us. Applying the model 473 
in this cohort of differing case-mix and ethnicity was considered a good test of the generalisability of 474 
the tool. The similar discriminatory performance herein, may suggest ethnicity is not a key 475 
determinant of prognosis. However, we recognise that follow-up duration in the Singaporean cohort 476 
is short, and the model remains untested among many other healthcare, geographic and ethnic 477 
contexts.   Finally, our comparisons to the EAU, NCCN and CAPRA stratification criteria are pragmatic 478 
but potentially unfair. These models are intended to delineate patients into groups of risk, rather 479 
than offering predictions of 10- or 15-year risk. However, these are widely used clinical models such 480 
that these comparisons may be of interest to PCa specialists, particularly in the absence of 481 
equivalent models to compare against.  482 
In conclusion, we have developed an individualised prognostication and decision-making tool for use 483 
at the point of PCa diagnosis. For the first time to our knowledge, this simultaneously presents 484 
individualised estimates of cancer-specific and overall survival outcomes and can model the impact 485 
of treatment on these outcomes. The accuracy of the model is promising across populations, and 486 
provides encouraging levels of discrimination in two validation cohorts. This model underpins a 487 
proposed new web-based tool and decision-aid to inform the decision-making process for patients 488 
and clinicians. Further external validation of the model should be established to explore accuracy 489 
and generalisability across other contexts – particularly testing validity amongst non-Caucasians and 490 
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